Tianru Jin

Tianru Jin, PhD, MD

Homeobox Genes and Human Diseases

Homeodomain (HD) proteins, encoded by homeobox genes, are critically implicated in many physiological and pathological cellular processes, including embryogenesis, gene expression, cell cycle, endocrine/neural functions and tumorigenesis. HD proteins, like many other transcription factors, are not expressed as specifically as their down-stream target genes.

My laboratory is interested in studying a fundamentally important biological question: what are the mechanisms which enable a single HD protein to exert its multiple biological functions in a cell type specific manner.

One of the model molecules currently used in my lab to address this question is the caudal related HD protein Cdx-2. In vivo experiments elucidated that Cdx-2 is haplo-insufficient in selected tissues/cells. Cdx-2+/- mice develop multiple intestinal polyps within three months after birth.

Our in vitro studies indicate that Cdx-2 requires some yet to be identified cell type specific component(s) to activate selected target promoters, including its own promoter (auto-regulation). My working hypotheses is: Cdx-2 is able to recruit both co-activators (such as CBP/p300) and co-repressors (to be identified), while cell type specific physiological and pathological signals are implicated in modulating the balance between these recruitment events. Different in vivo and in vitro approaches will be used to examine these hypotheses in detail.

Another ongoing project in my lab is to examine POU homeobox gene expression in malignant cells. We have identified the expression of four POU genes in human mammary gland. Two of them, OCT3 and OCT11, were only detectable in malignant cell lines and primary human breast tumors. We plan to extend this study into other cancerous cells, such as leukemia, lymphoma and myeloma cells. Information gained from this study could be useful for diagnosis and prognosis. In addition, we plan to examine the feasibility of using promoters of these POU genes as tools to specifically deliver genes for therapeutic purposes.
J Mol Cell Biol. 2017 Aug 18;:
Zeng K, Tian L, Sirek A, Shao W, Liu L, Chiang YT, Chernoff J, Ng DS, Weng J, Jin T
Front Pharmacol. 2017;8:362
Liu W, Son DO, Lau HK, Zhou Y, Prud'homme GJ, Jin T, Wang Q
Sci Immunol. 2017 Apr 21;2(10):
Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA
Cell Death Dis. 2017 Jan 19;8(1):e2559
Tian L, Song Z, Shao W, Du WW, Zhao LR, Zeng K, Yang BB, Jin T
Endocrinology. 2016 Dec 14;:jc20161596
Zeng K, Tian L, Patel R, Shao W, Song Z, Liu L, Manuel J, Ma X, McGilvray I, Cummins CL, Weng J, Jin T
Am J Physiol Endocrinol Metab. 2016 Aug 9;:ajpendo.00069.2016
Jin T, Weng J
Cell Rep. 2016 Jun 29;
Revelo XS, Ghazarian M, Chng MH, Luck H, Kim JH, Zeng K, Shi SY, Tsai S, Lei H, Kenkel J, Liu CL, Tangsombatvisit S, Tsui H, Sima C, Xiao C, Shen L, Li X, Jin T, Lewis GF, Woo M, Utz PJ, Glogauer M, Engleman E, Winer S, Winer DA
Diabetes. 2016 May 13;
Liu R, Wang H, Xu B, Chen W, Turlova E, Dong N, Sun CL, Lu Y, Fu H, Shi R, Barszczyk A, Yang D, Jin T, Mannucci E, Feng ZP, Sun HS

Pages